-
1.发明申请公开(公告)号：US20170172993A1
公开(公告)日：2017-06-22
申请号：US15449615
申请日：2017-03-03
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying Wang , Jason Brewer , Anil Vasudevan , Yanbin Lao , Charles Hutchins , Hongyu Zhao , Huan-Qiu Li
IPC: A61K31/454 , A61K31/4192 , A61K31/4025 , A61K31/4178 , A61K31/397
Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
-
2.发明申请Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy 有权氨基四氢化萘和氨基茚满衍生物，含有它们的药物组合物及其在治疗中的应用公开(公告)号：US20150111875A1
公开(公告)日：2015-04-23
申请号：US14517205
申请日：2014-10-17
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying Wang , Jason Brewer , Anil Vasudevan , Yanbin Lao , Charles Hutchins , Hongyu Zhao , Huan-Qiu Li
IPC: C07D403/14 , C07D405/14 , C07D403/10
CPC classification number: A61K31/454 , A61K31/397 , A61K31/4025 , A61K31/4178 , A61K31/4192 , C07D205/04 , C07D207/273 , C07D233/42 , C07D401/12 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14
Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
Abstract translation: 本发明涉及式（I）的氨基四氢化萘和氨基茚满衍生物或其生理上耐受的盐。 本发明涉及包含这种氨基四氢化萘和氨基茚满衍生物的药物组合物，以及这种氨基四氢化萘和氨基茚满衍生物用于治疗目的的用途。 氨基四氢化萘和氨基茚满衍生物是GlyT1抑制剂。
-
3.发明申请4,5- DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权4,5-二氢吡唑衍生物，含有它们的药物组合物及其在治疗中的使用公开(公告)号：US20160075691A1
公开(公告)日：2016-03-17
申请号：US14849470
申请日：2015-09-09
Applicant: ABBVIE DEUTSCHLAND GMBH & CO. KG , ABBVIE INC.
Inventor： Wilhelm Amberg , Jason Brewer , Charles Hutchins , Udo Lange , Yanbin Lao , Huan-Qiu Li , Frauke Pohlki , Anil Vasudevan , Ying Wang , Hongyu Zhao
IPC: C07D403/12 , C07D401/14
CPC classification number: C07D403/12 , C07D401/14
Abstract: The present invention relates to 4,5-dihydropyrazole derivatives of the formula (I) and physiologically tolerated salts thereof which are GlyT1 inhibitors. The invention further relates to pharmaceutical compositions comprising such 4,5-dihydropyrazole derivatives, and the use of such 4,5-dihydropyrazole derivatives for therapeutic purposes.
Abstract translation: 本发明涉及式（I）的4,5-二氢吡唑衍生物及其生理学上耐受的盐，它们是GlyT1抑制剂。 本发明还涉及包含这种4,5-二氢吡唑衍生物的药物组合物，以及这些用于治疗目的的这种4,5-二氢吡唑衍生物的用途。
-
公开(公告)号：US20190290645A1
公开(公告)日：2019-09-26
申请号：US16275938
申请日：2019-02-14
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying Wang , Jason Brewer , Anil Vasudevan , Yanbin Lao , Charles Hutchins , Hongyu Zhao , Huan-Qiu Li
IPC: A61K31/501 , A61K31/4433 , A61K31/4192 , A61K31/4178 , C07D405/04 , A61K31/397 , C07D311/58 , C07D405/14 , A61K31/4155
Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
-
5.发明授权Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy 有权氨基荧光素，氨基硫辛烷和氨基-1,2,3,4-四氢喹啉衍生物，含有它们的药物组合物及其在治疗中的用途公开(公告)号：US09586945B2
公开(公告)日：2017-03-07
申请号：US14517034
申请日：2014-10-17
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying Wang , Jason Brewer , Anil Vasudevan , Yanbin Lao , Charles Hutchins , Hongyu Zhao , Huan-Qiu Li
IPC: C07D405/04 , C07D405/14 , C07D311/58 , A61K31/352
CPC classification number: A61K31/501 , A61K31/397 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/4433 , C07D311/58 , C07D405/04 , C07D405/14
Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
Abstract translation: 本发明涉及包含这种氨基苯并二氢吡喃，氨基硫辛烷和氨基-1,2,3,4-四氢喹啉衍生物的药物组合物，以及用于治疗目的的这种氨基苯并二氢吡喃，氨基硫辛烷和氨基-1,2,3,4-四氢喹啉衍生物的用途。 氨基苯并二氢吡喃，氨基硫色烷和氨基-1,2,3,4-四氢喹啉衍生物是GlyT1抑制剂。
-
Patent Agency Ranking
6.发明授权Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy 有权氨基四氢化萘和氨基茚满衍生物，含有它们的药物组合物及其在治疗中的应用公开(公告)号：US09586942B2
公开(公告)日：2017-03-07
申请号：US14517205
申请日：2014-10-17
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying Wang , Jason Brewer , Anil Vasudevan , Yanbin Lao , Charles Hutchins , Hongyu Zhao , Huan-Qiu Li
IPC: C07D403/12 , C07D401/12 , C07D233/42 , C07D207/273 , C07D205/04 , C07D403/14 , C07D403/10 , C07D405/14 , A61K31/4164
CPC classification number: A61K31/454 , A61K31/397 , A61K31/4025 , A61K31/4178 , A61K31/4192 , C07D205/04 , C07D207/273 , C07D233/42 , C07D401/12 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14
Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
Abstract translation: 本发明涉及包含这种氨基四氢化萘和氨基茚满衍生物的药物组合物，以及这种氨基四氢化萘和氨基茚满衍生物用于治疗目的的用途。 氨基四氢化萘和氨基茚满衍生物是GlyT1抑制剂。
-
公开(公告)号：US20210130346A1
公开(公告)日：2021-05-06
申请号：US16605039
申请日：2017-04-14
Applicant: AbbVie Inc.
Inventor： David Hardee , Jason Brewer , Lisa Hasvold , Dachun Liu , Keith McDaniel , Michael Schrimpf , George Sheppard
IPC: C07D471/04 , A61P35/04
Abstract: Compounds of formula (I), wherein R1, R2, R3, R5, R6, R7, A1, A2, A3, A4, X1, and X2 have any of the values defined in the specification and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS are provided. Pharmaceutical compositions comprising of compounds of formula (I) are also provided.
-
8.发明申请公开(公告)号：US20190290632A1
公开(公告)日：2019-09-26
申请号：US16276144
申请日：2019-02-14
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying Wang , Jason Brewer , Anil Vasudevan , Yanbin Lao , Charles Hutchins , Hongyu Zhao , Huan-Qiu Li
IPC: A61K31/454 , C07D405/14 , C07D403/10 , A61K31/4192 , A61K31/4178 , A61K31/4025 , C07D403/12 , C07D403/14 , C07D207/273 , C07D205/04 , C07D401/12 , C07D233/42 , A61K31/397
Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
-
公开(公告)号：US20170173009A1
公开(公告)日：2017-06-22
申请号：US15449565
申请日：2017-03-03
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying Wang , Jason Brewer , Anil Vasudevan , Yanbin Lao , Charles Hutchins , Hongyu Zhao , Huan-Qiu Li
IPC: A61K31/501 , A61K31/4433 , A61K31/4155 , A61K31/4192 , A61K31/4178 , A61K31/397
Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
-
10.发明授权4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy 有权4,5-二氢吡唑衍生物，含有它们的药物组合物及其在治疗中的用途公开(公告)号：US09550754B2
公开(公告)日：2017-01-24
申请号：US14849470
申请日：2015-09-09
Applicant: ABBVIE DEUTSCHLAND GMBH & CO. KG , ABBVIE INC.
Inventor： Wilhelm Amberg , Jason Brewer , Charles Hutchins , Udo Lange , Yanbin Lao , Huan-Qiu Li , Frauke Pohlki , Anil Vasudevan , Ying Wang , Hongyu Zhao
IPC: C07D403/12 , C07D401/14
CPC classification number: C07D403/12 , C07D401/14
Abstract: The present invention relates to 4,5-dihydropyrazole derivatives of the formula (I) and physiologically tolerated salts thereof which are GlyT1 inhibitors. The invention further relates to pharmaceutical compositions comprising such 4,5-dihydropyrazole derivatives, and the use of such 4,5-dihydropyrazole derivatives for therapeutic purposes.
Abstract translation: 本发明涉及式（I）的4,5-二氢吡唑衍生物及其生理学上耐受的盐，它们是GlyT1抑制剂。 本发明还涉及包含这种4,5-二氢吡唑衍生物的药物组合物，以及这些用于治疗目的的这种4,5-二氢吡唑衍生物的用途。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.018 seconds)
